Lupin Q3 net profit beats expectations, but Street awaits more triggers The move impacts multinational drugmakers, like Abbott Laboratories Ltd and GlaxoSmithKline Plc, and a number of local firms, including Lupin Ltd, Cadila Healthcare Ltd and Ipca Ltd, all of whom sell drugs added to the list. Photo: Bloomberg 1 min read Share Via Read Full Story Lupin's December quarter performance was led by a recovery in US sales growth, though domestic sales also revived after facing covid-19 led disruptions. US, which remains the largest market and drives overall earnings, grew well during the quarter. North America sales, contributing 37% to overall revenues, grew 4.8% year-on-year. US sales, at $188 million, were slightly higher than $186 million seen in the previous year and $180 million in the previous quarter. The quarter saw three product launches in the US market, taking the number of products in the US generics market to 169.